Impact of switch of vascular access type on key clinical and laboratory parameters in chronic haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2194-2200

  Wystrychowski, Grzegorz ^a,b   Kitzler, Thomas M ^a,c   Thijssen, Stephan ^a   Usvyat, Len ^a   Kotanko, Peter ^a,d   Levin, Nathan W ^a  

^a RENAL RESEARCH INSTITUTE   (United States)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

Arteriovenous fistula; Arteriovenous graft; Haemodialysis; Vascular access; Venous catheter

Indexed keywords

ERYTHROPOIETIN; SERUM ALBUMIN;

ADULT; AGED; ANEMIA; ARTERIOVENOUS FISTULA; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INTRAVENOUS CATHETER; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VASCULAR ACCESS;

ARTERIOVENOUS SHUNT, SURGICAL; CATHETERS, INDWELLING; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 67649793956     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp052     Document Type: Article

References (35)

1. Dhingra RK, Young EW, Hulbert-Shearon TE et al. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443-1451
2. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int 2002; 62: 620-626
3. U.S. Renal Data System: USRDS. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007
4. Canaud B, Senecal L, Leray-Moragues H et al. Vascular access, an underestimated source of inflammation in dialysis patients. Nephrologie 2003; 24: 353-358
5. Fux CA, Uehlinger D, Bodmer T et al. Dynamics of hemodialysis catheter colonization by coagulase-negative staphylococci. Infect Control Hosp Epidemiol 2005; 26: 567-574
6. Goicoechea M, Caramelo C, Rodriguez P et al. Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. Nephrol Dial Transplant 2001; 16: 2188-2193
7. Strippoli GF, Manno C, Schena FP et al. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev 2003; CD003967
8. Teruel JL, Marcen R, Ocana J et al. Clinical significance of C-reactive protein in patients on hemodialysis: a longitudinal study. Nephron Clin Pract 2005; 100: c140-c145;
9. Del Vecchio L, Pozzoni P, Andrulli S et al. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005; 15: 137-141
10. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996; 7: 523-535
11. Asif A, Cherla G, Merrill D et al. Conversion of tunneled hemodialysis catheter-consigned patients to arteriovenous fistula. Kidney Int 2005; 67: 2399-2406
12. Di Iorio BR, Bellizzi V, Cillo N et al. Vascular access for hemodialysis: the impact on morbidity and mortality. J Nephrol 2004; 17: 19-25
13. Allon M, Daugirdas J, Depner TA et al. Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis 2006; 47: 469-477
14. Gotch FA. Urea kinetic modelling. Nephrol Dial Transplant 1995; 10: 2378-2379
15. Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998; 13 (Suppl 6): 10-14
16. Chand DH, Teo BW, Fatica RA et al. Influence of vascular access type on outcome measures in patients on maintenance hemodialysis. Nephron Clin Pract 2008; 108: c91-c98
17. Stenvinkel P, Heimburger O, Lindholm B et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15: 953-960
18. Lang CH, Frost RA, Nairn AC et al. TNF-alpha impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol Endocrinol Metab 2002; 282: E336-E347
19. Kalantar-Zadeh K, Block G, McAllister CJ et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307
20. Kalantar-Zadeh K, Ikizler TA, Block G et al. Malnutrition- inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42: 864-881
21. Thijssen S, Wystrychowski G, Usvyat L et al. Determinants of serum albumin concentration analyzed in a large cohort of patients on maintenance hemodialysis. J Ren Nutr 2007; 17: 70-74
22. Leavey SF, Strawderman RL, Young EW et al. Cross-sectional and longitudinal predictors of serum albumin in hemodialysis patients. Kidney Int 2000; 58: 2119-2128
23. Movilli E, Brunori G, Camerini C et al. The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients. Blood Purif 2006; 24: 387-393
24. Ishani A, Collins AJ, Herzog CA et al. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int 2005; 68: 311-318
25. Locatelli F, Andrulli S, Memoli B et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 991-998
26. Frede S, Fandrey J, Pagel H et al. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am J Physiol 1997; 273: R1067-R1071
27. Jelkmann WE, Fandrey J, Frede S et al. Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. AnnNYAcadSci 1994; 718: 300-309; discussion 309-311
28. Allen DA, Breen C, Yaqoob MM et al. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN- gamma and TNF-alpha. J Investig Med 1999; 47: 204-211
29. Movilli E, Cancarini GC, Zani R et al. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 111-114
30. Polkinghorne KR, McDonald SP, Atkins RC et al. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004; 15: 477-486
31. Xue JL, Dahl D, Ebben JP et al. The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 2003; 42: 1013-1019
32. Bonomo RA, Rice D, Whalen C et al. Risk factors associated with permanent access-site infections in chronic hemodialysis patients. Infect Control Hosp Epidemiol 1997; 18: 757-761
33. Astor BC, Eustace JA, Powe NR et al. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. J Am Soc Nephrol 2005; 16: 1449-1455
34. Wystrychowski G, Kitzler TM, Thijssen S et al. Effect of arteriovenous access type switch on key clinical parameters in hemodialysis patients. J Am Soc Nephrol 2008; 19: 469A
35. Allon M. Prophylaxis against dialysis catheter-related bacteremia: a glimmer of hope. Am J Kidney Dis 2008; 51: 165-168